Dec 23 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP ANNOUNCES SUCCESSFUL MEETING WITH THE FDA ON EFTILAGIMOD ALPHA PLUS CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC BREAST CANCER
- PATIENT POPULATION EXPANDED TO INCLUDE PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
- IMMUTEP'S CASH RUNWAY EXTENDED TO END OF 1ST HALF OF CALENDAR YEAR 2024
- FDA AGREED TO TEST 90MG EFTI DOSING IN COMBINATION WITH PACLITAXEL DRIVEN BY EXCELLENT SAFETY PROFILE OF AIPAC PHASE IIB TRIAL
- PHASE II PORTION OF MBC TRIAL IS EXPECTED TO BEGIN DURING Q1 OF 2023
News: IMM Immutep Announces Successful Meeting With The FDA On Eftilagimod Alpha Plus Chemotherapy...
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.035(8.05%) |
Mkt cap ! $558.7M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 48.5¢ | 44.5¢ | $2.743M | 5.852M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 55686 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 92898 | 2 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
46.5¢ |
Change
0.035 ( 6.90 %) |
||||
| Open | High | Low | Volume | ||
| 45.0¢ | 48.5¢ | 45.0¢ | 1500168 | ||
| Last updated 15.59pm 06/05/2024 ? | |||||
| IMM (ASX) Chart |